Thus, cumulative evidence has demonstrated YAP as a possible new molecular target for cancer therapy [15–17], and it is practical to seek an alternative Hippo-targeted agent with limited reproductive and genetic toxicity for endometrial cancer. The gene discussed is YAP1; the disease is endometrial cancer.